Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
Status:
Recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of niraparib and dostarlimab in treating small cell
lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of
PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged.
Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to
die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal
antibodies, such as dostarlimab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving niraparib and
dostarlimab may help to control the diseases.